NASDAQ$IMMX
Immix Biopharma Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
IMMX Q2 2024 — $20.0M revenue, 4.00 EPS
Quarterly Report on Form 10-Q, even if such results, changes. Immix Biopharma Inc reported Q2 2024 results. Diluted EPS came in at $4.00. Net income of $9.7M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $20.0M.
- Diluted EPS: $4.00.
- Net income: $9.7M.
Headline financials
Revenue & EPS history
Immix Biopharma · Revenue · Quarterly
$20M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-2.1%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
24%
5 / 21 earnings
Positive
+11.3%
Q2 2021
Best reaction
-11.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.8% | +3.0% | -23.4% | |
| Q4 2025 | +4.2% | +0.1% | +14.9% | |
| Q3 2025 | +2.5% | +14.6% | +95.2% | |
| Q4 2024 | +0.0% | -2.2% | -4.3% | |
| Q2 2025 | -2.6% | -8.4% | -9.2% | |
| Q1 2025 | -1.0% | -6.6% | +11.8% | |
| Q3 2024 | -11.3% | -10.2% | +20.3% | |
| Q2 2024 | -4.6% | -2.6% | -4.6% | |
| Q1 2024 | -2.7% | -1.8% | -9.4% | |
| Q4 2023 | -4.9% | -0.3% | -30.6% | |
| Q3 2023 | +5.0% | +4.1% | -0.5% | |
| Q2 2023 | -3.7% | -6.8% | +37.4% | |
| Q1 2023 | -5.9% | -19.2% | -9.1% | |
| Q4 2022 | -2.2% | -0.5% | +1.1% | |
| Q3 2021 | -8.6% | +25.6% | +69.5% | |
| Q3 2022 | -8.6% | +25.6% | +69.5% | |
| Q2 2022 | -4.9% | -7.7% | -26.8% | |
| Q1 2021 | -5.0% | -7.1% | +73.6% | |
| Q1 2022 | -5.0% | -7.1% | +73.6% | |
| Q4 2021 | +11.3% | +16.4% | -37.6% | |
| Q2 2021 | +11.3% | +16.4% | -37.6% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro